Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark Cunningham is active.

Publication


Featured researches published by Mark Cunningham.


American Journal of Respiratory and Critical Care Medicine | 2008

Deleterious Role of TLR3 during Hyperoxia-induced Acute Lung Injury

Lynne A. Murray; Darryl A. Knight; Laura McAlonan; Rochelle L. Argentieri; Amrita Joshi; Furquan Shaheen; Mark Cunningham; Lena Alexopolou; Richard A. Flavell; Robert T. Sarisky; Cory M. Hogaboam

RATIONALE Acute respiratory distress syndrome (ARDS) manifests clinically as a consequence of septic and/or traumatic injury in the lung. Oxygen therapy remains a major therapeutic intervention in ARDS, but this can contribute further to lung damage. Patients with ARDS are highly susceptible to viral infection and it may be due to altered Toll-like receptor (TLR) expression. OBJECTIVES To evaluate the role of TLR3 in ARDS. METHODS TLR3 expression and signaling was determined in airway epithelial cells after in vitro hyperoxia challenge. Using a murine model of hyperoxia-induced lung injury, the role of TLR3 was determined using either TLR3-gene deficient mice or a specific neutralizing antibody directed to TLR3. MEASUREMENTS AND MAIN RESULTS Increased TLR3 expression was observed in airway epithelial cells from patients with ARDS. Further, hyperoxic conditions alone were a major stimulus for increased TLR3 expression and activation in cultured human epithelial cells. Interestingly, TLR3(-/-) mice exhibited less acute lung injury, activation of apoptotic cascades, and extracellular matrix deposition after 5 days of 80% oxygen compared with wild-type (TLR3(+/+)) mice under the same conditions. Administration of a monoclonal anti-TLR3 antibody to TLR3(+/+) mice exposed to hyperoxic conditions likewise protected these mice from lung injury and inflammation. CONCLUSIONS The potential for redundancy in function as well as cross-talk between distinct TLRs may indeed contribute to whether the inflammatory cascade can be effectively disrupted once signaling has been initiated. Together, these data show that TLR3 has a major role in the development of ARDS-like pathology in the absence of a viral pathogen.


Viral Immunology | 2008

Generation of a Protective T-Cell Response Following Coronavirus Infection of the Central Nervous System Is Not Dependent on IL-12/23 Signaling

Katherine S. Held; William G. Glass; Yevgeniya I. Orlovsky; Kimberly Shamberger; Ted Petley; Patrick Branigan; Jill Carton; Heena Beck; Mark Cunningham; Jacqueline Benson; Thomas E. Lane

The functional role of IL-12 and IL-23 in host defense and disease following viral infection of the CNS was determined. Instillation of mouse hepatitis virus (MHV, a positive-strand RNA virus) into the CNS of mice results in acute encephalitis followed by a chronic immune-mediated demyelinating disease. Antibody-mediated blocking of either IL-23 (anti-IL-23p19) or IL-12 and IL-23 (anti-IL-12/23p40) signaling did not mute T-cell trafficking into the CNS or antiviral effector responses and mice were able to control viral replication within the brain. Therapeutic administration of either anti-IL-23p19 or anti-IL-12/23p40 to mice with viral-induced demyelination did not attenuate T-cell or macrophage infiltration into the CNS nor improve clinical disease or diminish white matter damage. In contrast, treatment of mice with anti-IL-12/23p40 or anti-IL-23p19 resulted in inhibition of the autoimmune model of demyelination, experimental autoimmune encephalomyelitis (EAE). These data indicate that (1) IL-12 and IL-23 signaling are dispensable in generating a protective T-cell response following CNS infection with MHV, and (2) IL-12 and IL-23 do not contribute to demyelination in a model independent of autoimmune T-cell-mediated pathology. Therefore, therapeutic targeting of IL-12 and/or IL-23 for the treatment of autoimmune diseases may offer unique advantages by reducing disease severity without muting protective responses following viral infection.


Archive | 2006

Anti-IL-23 antibodies, compositions, methods and uses

Jacqueline Benson; Mark Cunningham; Cynthia Duchala; Jill Giles-Komar; Jinquan Luo; Michael Rycyzyn; Raymond Sweet


Archive | 2006

Human anti-il-23 antibodies, compositions, methods and uses

Jacqueline Benson; Jill Carton; Mark Cunningham; Yevgeniya I. Orlovsky; Robert Rauchenberger; Raymond Sweet


Archive | 2004

IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES

Jacqueline Benson; Mark Cunningham


Archive | 2009

Toll-like receptor 3 antagonists

Mark Cunningham; Yiqing Feng; Katharine Heeringa; Jinquan Luo; Robert Rauchenberger; Mark Rutz; Lani San Mateo; Robert T. Sarisky; Raymond Sweet; Fang Teng; Alexey Teplyakov; Sheng-Jiun Wu


Archive | 2011

Nucleic Acids Encoding Human Anti-IL-23 Antibodies

Jacqueline Benson; Jill Carton; Mark Cunningham; Yevgeniya I. Orlovsky; Robert Rauchenberger; Raymond Sweet


Archive | 2006

Tlr3 glycosylation site muteins and methods of use

Karen E. Duffy; Mark Cunningham; Mouhamadou L. Mbow; Robert T. Sarisky


Archive | 2013

Polynucleotides encoding Toll-Like Receptor 3 antagonists

Mark Cunningham; Yiqing Feng; Katharine Heeringa; Jinquan Luo; Robert Rauchenberger; Mark Rutz; Lani San Mateo; Robert T. Sarisky; Raymond Sweet; Fang Teng; Alexey Teplyakov; Sheng-Jiun Wu


Archive | 2013

Toll-Like 3 Receptor Antagonists

Mark Cunningham; Yiqing Feng; Katharine Heeringa; Jinquan Luo; Robert Rauchenberger; Mark Rutz; Lani San Mateo; Robert T. Sarisky; Raymond Sweet; Fang Teng; Alexey Teplyakov; Sheng-Jiun Wu

Collaboration


Dive into the Mark Cunningham's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Fang Teng

Janssen Pharmaceutica

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark Rutz

Janssen Pharmaceutica

View shared research outputs
Researchain Logo
Decentralizing Knowledge